Liqing Kang
- Oncology top 5%
- CAR-T cell therapy research 62
- Hematology top 10%
- Multiple Myeloma Research and Treatments 6
-
- Immune Cell Function and Interaction 5
- Genetics top 10%
- Virus-based gene therapy research 10
-
- Nanowire Synthesis and Applications 6
-
- Viral Infectious Diseases and Gene Expression in Insects 7
-
- Lymphoma Diagnosis and Treatment 7
-
- Advancements in Semiconductor Devices and Circuit Design 6
- Cited by
- OncologyHematologyImmunology
- Partner nations
- ChinaUnited StatesTaiwan
In The Last Decade
Liqing Kang
60 papers receiving 932 citations
Peers
Comparison fields: 5 of 64
- Oncology 722
- Hematology 123
- Immunology 188
- Genetics 204
- Biomedical Engineering 246
Countries citing papers authored by Liqing Kang
This map shows the geographic impact of Liqing Kang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Liqing Kang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Liqing Kang more than expected).
Fields of papers citing papers by Liqing Kang
This network shows the impact of papers produced by Liqing Kang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Liqing Kang. The network helps show where Liqing Kang may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Liqing Kang, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 0 | |
| 2 | 2024 | 0 | |
| 3 | 2024 | 23 | |
| 4 | 2024 | 4 | |
| 5 | 2023 | 5 | |
| 6 | 2023 | 0 | |
| 7 | 2023 | 8 | |
| 8 | 2022 | 62 | |
| 9 | 2022 | 17 | |
| 10 | 2022 | 10 | |
| 11 | 2022 | 6 | |
| 12 | 2022 | 25 | |
| 13 | 2022 | 19 | |
| 14 | 2021 | 35 | |
| 15 | 2020 | 49 | |
| 16 | 2019 | 2 | |
| 17 | 2019 | 12 | |
| 18 | 2017 | 26 | |
| 19 | 2017 | 1 | |
| 20 | 2017 | 0 |
About Liqing Kang
Liqing Kang is a scholar working on Oncology, Hematology and Immunology, having authored 68 papers that have together received 944 indexed citations. Recurring topics across this work include CAR-T cell therapy research (62 papers), Virus-based gene therapy research (10 papers), Viral Infectious Diseases and Gene Expression in Insects (7 papers), Lymphoma Diagnosis and Treatment (7 papers), Multiple Myeloma Research and Treatments (6 papers), Advancements in Semiconductor Devices and Circuit Design (6 papers), Nanowire Synthesis and Applications (6 papers) and Immune Cell Function and Interaction (5 papers). The work is most often cited by research in Oncology (722 citations), Hematology (123 citations) and Immunology (188 citations). Liqing Kang has collaborated with scholars based in China, United States and Taiwan. Frequent co-authors include Lei Yu, Nan Xu, Depei Wu, Xiaoyan Lou, Depei Wu, Zhiqiang Yan, Xiaowen Tang, Minghao Li, Changju Qu and Haiping Dai. Their work appears in journals such as Blood, Frontiers in Immunology, Biomarker Research, Molecular Therapy — Oncolytics and Blood Advances.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.